PROVIDER PROFILE · NPI 1689724965

Haiying ChengM.D.

Hematology-OncologyBronx, NYI

MEDICARE UTILIZATION · PART B · 2024

Total beneficiaries

123

Unique beneficiaries

—

Total services

272

Distinct HCPCS

Medicare payment

$29K

Peer benchmark

Total Medicare services vs. 628 Hematology-Oncology providers in NY — bottom quintile (cohort median 883).

PRESCRIBING · PART D · 2024

Total Rx claims

130

Beneficiaries

—

Total drug cost

$998K

Distinct drugs

Brand share

46.2%

Top prescribed drugs

Osimertinib Mesylate60 claims

Ondansetron Hcl34 claims

Prochlorperazine Maleate22 claims

Mirtazapine14 claims

QUALITY · MIPS · 2024

Final MIPS score

100.0

Quality

27.5

Cost

68.4

Improvement activities

40.0

Promoting interop.

100.0

Payment adjustment

1.05%

Group

INDUSTRY PAYMENTS · OPEN PAYMENTS · 2024

Total received

$7K

Payment records

By payment type

Consulting Fee$4K

Honoraria$2K

Food and Beverage$277

Education$53

REFERRAL NETWORK

Where Haiying Cheng's patients come from & go

Directional shared-patient flow from Medicare claims — who sends patients to this provider (inbound) and where this provider's patients go next (outbound). 6 inbound referrers · 0 outbound destinations.

Receives referrals from

Inbound — who sends patients here

Physician	Patients	Visits
Jesus Anampa Mesias Medical Oncology · Bronx, NY	20	56
Lakshmi Rajdev Medical Oncology · Bronx, NY	19	92
Jennifer Chuy Medical Oncology · Bronx, NY	18	98
Noah Kornblum Medical Oncology · Bronx, NY	14	23
Sanjay Goel Medical Oncology · New Brunswick, NJ	13	72
PACKER, STUART	11	65

Refers patients to

Outbound — where patients go next

No outbound pairs above the suppression threshold.

Source: CMS Physician Shared Patient Patterns (30-day window, Medicare FFS). Direction = a beneficiary seen by the first provider, then the second, within 30 days; a proxy for referral, not a documented referral. Pairs with fewer than 11 shared beneficiaries are suppressed.

CROSS-REFERENCE

Related data on other Healthparse brands

ProviderScore

OIG/SAM exclusion screening, sanctions history